An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
908 Devices (NASDAQ: MASS) has launched a public offering of 2,750,000 shares of its common stock, with an additional 412,500 shares available to underwriters for purchase. The funds raised will be used for working capital, research and development, commercial expansion, and potential acquisitions. The offering is subject to market conditions and awaits the effectiveness of a registration statement with the SEC.
Positive
Intended use of proceeds includes funding for research and development to enhance product applications.
Plans to expand commercial operations and accelerate investments.
Potential for acquisition of complementary businesses, which could bolster growth.
Negative
The offering could lead to shareholder dilution.
Market conditions introduce uncertainty regarding the successful completion of the offering.
BOSTON--(BUSINESS WIRE)--
908 Devices Inc. (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the launch of a public offering of shares of its common stock, with 2,750,000 shares being offered by the Company pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”). The underwriters will have a 30-day option to purchase up to an additional 412,500 shares of common stock from the Company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
The Company intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, for working capital and general corporate purposes, including: (1) to fund its research and development efforts to expand the applications of its current devices and to create enhanced products with its platform of technologies; (2) to expand its commercial operations and accelerate planned investments; and (3) to acquire complementary businesses, products, services or technologies.
Cowen and SVB Leerink will act as lead book-running managers for the proposed offering. William Blair and Stifel will be book-running managers for the proposed offering.
The proposed offering will be made only by means of a prospectus. A copy of the preliminary prospectus may be obtained from: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 833-297-2926, or by email at PostSaleManualRequests@broadridge.com; or SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, telephone: 1-800-808-7525, ext. 6105, or by email at syndicate@svbleerink.com.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About 908 Devices
908 Devices is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it conducts research, designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation, and machine learning.
Forward Looking Statements
This press release includes “forward looking information,” including with respect to the timing of the public offering and our intended use of proceeds. Words or phrases such as “will,” “believes,” “intends” or “expects” or similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and assumptions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in the preliminary prospectus and the Company’s most recent annual report on Form 10-K and quarterly report on Form 10-Q as filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus related to the proposed public offering as filed with the SEC. These risks and uncertainties may cause actual results to differ materially from any results expressed or implied by any forward-looking statement. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as required by law.
What is the size of the public offering announced by 908 Devices (MASS)?
908 Devices announced a public offering of 2,750,000 shares of its common stock, with an option for underwriters to purchase an additional 412,500 shares.
What will the proceeds from 908 Devices' (MASS) public offering be used for?
The proceeds will be used for working capital, R&D to enhance product applications, expansion of commercial operations, and potential acquisitions.
When will the public offering by 908 Devices (MASS) be completed?
The public offering is subject to market conditions, and there is no assurance as to when it will be completed.
Who are the lead managers for the public offering of 908 Devices (MASS)?
Cowen and SVB Leerink are acting as lead book-running managers for the offering.
What risks are associated with the public offering of 908 Devices (MASS)?
The offering may result in shareholder dilution, and market conditions may affect its completion.
